Coya Therapeutics, Inc.

COYA Nasdaq SEC CIK 1835022
Follow Coya Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $234.1K −93.4% vs same quarter last year
Net income −$10.6M −401.8% vs same quarter last year
EPS, diluted −$0.45 −246.2% vs same quarter last year
Operating cash flow −$7.2M −539.9% vs same quarter last year
Revenue by quarter
$2K
$257.9K
$163.6K
$3.6M
$4M
$251.1K
$243.7K
$234.1K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$7.9M−$21.2M
FY24$3.6M−$14.9M
FY23$6M−$8M
FY22$0−$12.2M
FY21-−$4.9M
FY20--
MarginsShare of revenue
  • Operating margin
  • Net margin
−600%−400%−200%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−283.9%−267.1%
FY24−485.4%−418.7%
FY23−131.7%−133.1%
FY22--
FY21--
FY20--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Coya Therapeutics
  • Healthcare median
−600%−400%−200%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearCoya TherapeuticsHealthcare median
FY25−267.1%−30.6%
FY24−418.7%−47%
FY23−133.1%−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%